iNeo-Vac-P01
Phase 1Biologic
iNeo-Vac-P01 is one of 51 biologic programs targeting Neoadjuvant Therapy. It is currently in Phase 1.
1
Indications
5
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Neoadjuvant Therapy
#DrugCompanyPhaseTrials
1Lenvima
EisaiPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Paraplatin
AAvyxa
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Keytruda
Merck & Co.Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 3
Avastin
RochePhase 2
Beyfortus
BeiGenePhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Tagrisso
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer2 trials
Malignant Tumor1 trial
Patients With Solid Tumors1 trial
Neoadjuvant Therapy1 trial
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05307835·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iNeo-Vac-P01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSir Run Run Shaw Hospital